• Xia Zhao, Haiyan Bian, Fengyun Hao, Shihong Shao, Chuanhong Wu, Qian Zhang, Mingxuan Wu, Zhiqiang Li, and Chengwen Gao.
• Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, China.
• Ann. Med. 2024 Dec 1; 56 (1): 24195562419556.

BackgroundTransformed lymphoma occurs when indolent lymphoma transforms into more aggressive lymphoma usually associated with poor prognosis.MethodsIn this study, we analysed the immunophenotypes, prognostic factors and outcomes of 35 patients with transformed lymphoma from among 306 marginal zone lymphoma (MZL), 544 follicular lymphoma (FL) and 871 chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) cases. In addition, we performed whole-exome sequencing study of seven transformed MZL (tMZL) cases.ResultsOur results demonstrate that the median time from indolent lymphoma diagnosis to transformed DLBCL was 35 months (range, 14-53 months). The 5-year overall survival (OS) and progression-free survival (PFS) rates after histological transformation (HT) were 50% and 26%, respectively. Kaplan-Meier survival analysis revealed that asynchronous HT and transformed CLL/SLL (tCLL/SLL) were significant adverse prognostic factors for OS after DLBCL HT. We identified mutations involvement in chromatin remodelling (CREBBP and EP300) and regulators of NF-κB signalling (TNFAIP3, BCL10, MYD88, CD79B and CARD11) were affected in tMZL.ConclusionWhole-exome sequencing and copy-number analysis revealed that tMZL derives from the divergent evolution of an ancestral common progenitor clone (CPC). Collectively, this study provides clinicopathological characteristics of three common types of transformed lymphomas and the genetic profile of tMZL with diagnostic and therapeutic implications.

33 keywords...

hide…